Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy

Journal of Cardiovascular Pharmacology

Volumn 67, Issue 5, 2016, Pages 402-411

  Grune, Jana ^a   Benz, Verena ^a   Brix, Sarah ^a   Salatzki, Janek ^a   Blumrich, Annelie ^a   Höft, Beata ^a   Klopfleisch, Robert ^b   Foryst Ludwig, Anna ^a,c   Kolkhof, Peter ^d   Kintscher, Ulrich ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^d BAYER PHARMA AG   (Germany)

Author keywords

aldosterone; cardiac hypertrophy; gene expression; mineralocorticoids

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; EPLERENONE; FINERENONE; MINERALOCORTICOID RECEPTOR; TROPONIN T; TROPONIN T TYPE 2; UNCLASSIFIED DRUG; MINERALOCORTICOID ANTAGONIST; NAPHTHYRIDINE DERIVATIVE; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL CARDIAC HYPERTROPHY; GENE EXPRESSION PROFILING; HEART LEFT VENTRICLE MASS; HEART VENTRICLE OVERLOAD; HEART VENTRICLE PRESSURE; HEART VENTRICLE REMODELING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CARDIOMEGALY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; CARDIOMEGALY; DISEASE MODELS, ANIMAL; GENE EXPRESSION; MALE; MICE; MICE, INBRED C57BL; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NAPHTHYRIDINES; NATRIURETIC PEPTIDE, BRAIN; SPIRONOLACTONE; TROPONIN T; VENTRICULAR REMODELING;

EID: 84957825109     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000366     Document Type: Article

References (37)

1. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension. 2005;46:1227-1235.
2. Delcayre C, Silvestre JS. Aldosterone and the heart: towards a physiological function? Cardiovasc Res. 1999;43:7-12.
3. Kolkhof P, Borden SA. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol. 2012;350: 310-317.
4. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
5. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341: 709-717.
6. Zannad F, Gattis Stough W, Rossignol P, et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012;33:2782-2795.
7. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364: 11-21.
8. Young MJ. Targeting the mineralocorticoid receptor in cardiovascular disease. Expert Opin Ther Targets. 2013;17:321-331.
9. Fagart J, Hillisch A, Huyet J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010;285:29932-29940.
10. Barfacker L, Kuhl A, Hillisch A, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. Chem Med Chem. 2012;7:1385-1403.
11. Fliegner D, Schubert C, Penkalla A, et al. Female sex and estrogen receptor-beta attenuate cardiac remodeling and apoptosis in pressure overload. Am J Physiol Regul Integr Comp Physiol. 2010;298: R1597-R1606.
12. Franco V, Chen YF, Feng JA, et al. Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptidenull mice. Clin Exp Pharmacol Physiol. 2006;33:773-779.
13. Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64:69-78.
14. Qin W, Rudolph AE, Bond BR, et al. Transgenic model of aldosteronedriven cardiac hypertrophy and heart failure. Circ Res. 2003;93:69-76.
15. Schuhmacher J, Kohlsdorfer C, Buhner K, et al. High-throughput determination of the free fraction of drugs strongly bound to plasma proteins. J Pharm Sci. 2004;93:816-830.
16. Klopfleisch R, Lenze D, Hummel M, et al. The metastatic cascade is reflected in the transcriptome of metastatic canine mammary carcinomas. Vet J. 2011;190:236-243.
17. Klose P, Weise C, Bondzio A, et al. Is there a malignant progression associated with a linear change in protein expression levels from normal canine mammary gland to metastatic mammary tumors? J Proteome Res. 2011;10:4405-4415.
18. Amazit L, Le Billan F, Kolkhof P, et al. Finerenone impedes aldosteronedependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor Coactivator-1. J Biol Chem. 2015;290:21876-21889.
19. Frey N, Luedde M, Katus HA. Mechanisms of disease: hypertrophic cardiomyopathy. Nat Rev Cardiol. 2012;9:91-100.
20. Hwang PM, Sykes BD. Targeting the sarcomere to correct muscle function. Nat Rev Drug Discov. 2015;14:313-328.
21. Volpe M, Rubattu S, Burnett J Jr. Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J. 2014;35:419-425.
22. Gardner DG, Chen S, Glenn DJ, et al. Molecular biology of the natriuretic peptide system: implications for physiology and hypertension. Hypertension. 2007;49:419-426.
23. Kuhn M. Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ Res. 2003;93:700-709.
24. Kishimoto I, Rossi K, Garbers DL. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc Natl Acad Sci U S A. 2001;98:2703-2706.
25. Tokudome T, Horio T, Kishimoto I, et al. Calcineurin-nuclear factor of activated T cells pathway-dependent cardiac remodeling in mice deficient in guanylyl cyclase A, a receptor for atrial and brain natriuretic peptides. Circulation. 2005;111:3095-3104.
26. Cataliotti A, Tonne JM, Bellavia D, et al. Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation. 2011; 123:1297-1305.
27. Pharmacological review inspra drug approval Package. FDA US, Food and Drug Administration; 2003:21-437. S-002. http://www.accessdata.fda.gov/drugsaftda-docs/nda/2003/21-437S002-Inspra-Pharmr.pdf. Accessed December 1, 2015.
28. Kuster GM, Kotlyar E, Rude MK, et al. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation. 2005;111:420-427.
29. Kolkhof P, Nowack C, Eitner F. Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens. 2015;24: 417-424.
30. Liu W, Zi M, Tsui H, et al. A novel immunomodulator, FTY-720 reverses existing cardiac hypertrophy and fibrosis from pressure overload by targeting NFAT (nuclear factor of activated T-cells) signaling and periostin. Circ Heart Fail. 2013;6:833-844.
31. Maejima Y, Usui S, Zhai P, et al. Muscle-specific RING finger 1 negatively regulates pathological cardiac hypertrophy through downregulation of calcineurin A. Circ Heart Fail. 2014;7:479-490.
32. Guo J, Mihic A, Wu J, et al. Canopy 2 attenuates the transition from compensatory hypertrophy to dilated heart failure in hypertrophic cardiomyopathy. Eur Heart J. 2015;36:2530-2540.
33. Morgan LA, Olzinski AR, Upson JJ, et al. Soluble epoxide hydrolase inhibition does not prevent cardiac remodeling and dysfunction after aortic constriction in rats and mice. J Cardiovasc Pharmacol. 2013;61:291-301.
34. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34: 2453-2463.
35. Pitt B, Anker SD, Bohm M, et al. Rationale and design of Miner Alocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail. 2015;17:224-232.
36. Ruilope LM, Agarwal R, Chan JC, et al. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol. 2014;40:572-581.
37. Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314:884-894.